ID

4465

Description

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma DISEASE CHARACTERISTICS: - Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement) - CD20^+ B-cell lymphoma or CD20^- B-cell and T-cell lymphoma allowed - B-cell NHL including the following: Stage III follicular lymphoma; Stage III follicular lymphoma and diffuse B-cell lymphoma; Lymphoblastic precursor B-cell lymphoma; Diffuse large cell B-cell lymphoma; Centroblastic; Immunoblastic; Plasmablastic; Anaplastic large cell; T-cell-rich B-cell lymphoma; Primary effusion lymphoma; Intravasal B-cell lymphoma; Primary mediastinal B-cell lymphoma; Mantle zone lymphoma, blastoid; Burkitt's lymphoma; Burkitt-like lymphoma; Aggressive marginal zone lymphoma (monocytoid); - T-cell NHL including the following: Lymphoblastic precursor T-cell lymphoma; Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS); Lennert's lymphoma; T-zone lymphoma; T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type; Anaplastic large cell lymphoma; ALK^+ - ALK^-; Extranodal NK/T-cell lymphoma, nasal type; Intestinal T/NK-cell lymphoma (with or without enteropathy); Hepatosplenic gamma-delta lymphoma; Subcutaneous panniculitis-like PTCL; Aggressive T/NK PTCL; Anaplastic large-cell NHL, NOS - Bone marrow involvement no more than 25% - No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract PATIENT CHARACTERISTICS: Age - 61 to 80 Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - Not specified Hematopoietic - WBC at least 2,500/mm^3; Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN); No active hepatitis infection Renal - Creatinine no greater than 2 times ULN Cardiovascular - No Canadian Cardiovascular Society class III or IV angina pectoris - No New York Heart Association class III or IV cardiac failure - Ejection fraction at least 50% - Fractional shortenings at least 25% by echocardiography or nuclear medicine examination Pulmonary - FEV1 at least 50% - Diffusion capacity at least 50% Other - No uncontrolled diabetes mellitus - No known hypersensitivity to any study medications - No other concurrent malignancy - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy Surgery - Not specified Other - Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study) - No other concurrent lymphoma therapy - No concurrent participation in another treatment study

Keywords

  1. 12/9/13 12/9/13 - Martin Dugas
  2. 12/22/14 12/22/14 - Martin Dugas
Uploaded on

December 9, 2013

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00052936 NHL

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Disease characteristics
Description

Disease characteristics

Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement); CD20^+ B-cell lymphoma or CD20^- B-cell and T-cell lymphoma allowed
Description

Aggressive non-Hodgkin's lymphoma (NHL)

Data type

boolean

B-cell NHL including the following: Stage III follicular lymphoma; Stage III follicular lymphoma and diffuse B-cell lymphoma; Lymphoblastic precursor B-cell lymphoma; Diffuse large cell B-cell lymphoma; Centroblastic; Immunoblastic; Plasmablastic; Anaplastic large cell; T-cell-rich B-cell lymphoma; Primary effusion lymphoma; Intravasal B-cell lymphoma; Primary mediastinal B-cell lymphoma; Mantle zone lymphoma, blastoid; Burkitt's lymphoma; Burkitt-like lymphoma; Aggressive marginal zone lymphoma (monocytoid)
Description

B-cell NHL

Data type

boolean

T-cell NHL including the following: Lymphoblastic precursor T-cell lymphoma; Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS); Lennert's lymphoma; T-zone lymphoma; T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type; Anaplastic large cell lymphoma; ALK^+ - ALK^-; Extranodal NK/T-cell lymphoma, nasal type; Intestinal T/NK-cell lymphoma (with or without enteropathy); Hepatosplenic gamma-delta lymphoma; Subcutaneous panniculitis-like PTCL; Aggressive T/NK PTCL; Anaplastic large-cell NHL, NOS
Description

T-cell NHL

Data type

boolean

Bone marrow involvement no more than 25%
Description

Bone marrow

Data type

boolean

No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract
Description

CNS / GI

Data type

boolean

Patient characteristics and prior concurrent therapy
Description

Patient characteristics and prior concurrent therapy

Age 61 to 80
Description

Age

Data type

boolean

ECOG 0-2 OR - Karnofsky 60-100%
Description

Performance Status

Data type

boolean

WBC at least 2,500/mm^3; Platelet count at least 100,000/mm^3
Description

Hematopoietic

Data type

boolean

Bilirubin no greater than 2 times upper limit of normal (ULN); No active hepatitis infection
Description

Hepatic

Data type

boolean

Creatinine no greater than 2 times ULN
Description

Renal

Data type

boolean

No Canadian Cardiovascular Society class III or IV angina pectoris; No New York Heart Association class III or IV cardiac failure; Ejection fraction at least 50%; Fractional shortenings at least 25% by echocardiography or nuclear medicine examination
Description

Cardiovascular

Data type

boolean

FEV1 at least 50%; Diffusion capacity at least 50%
Description

Pulmonary

Data type

boolean

No uncontrolled diabetes mellitus; No known hypersensitivity to any study medications; No other concurrent malignancy; HIV negative
Description

Other

Data type

boolean

No prior chemotherapy; No prior radiotherapy; Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study); No other concurrent lymphoma therapy; No concurrent participation in another treatment study
Description

Prior concurrent therapy

Data type

boolean

Medical Concepts
Description

Medical Concepts

Diagnosis
Description

Diagnosis

Data type

string

Alias
UMLS CUI
C0011900
SNOMED CT 2010_0731
439401001
Diagnostic Neoplasm Staging
Description

Diagnostic Neoplasm Staging

Data type

string

Alias
UMLS CUI
C0027646
Bone Marrow Involvement
Description

Bone Marrow Involvement

Data type

string

Alias
UMLS CUI
C1517677
Age
Description

Age

Data type

string

Alias
UMLS CUI
C0001779
SNOMED CT 2010_0731
102518004
ECOG performance status
Description

ECOG performance status

Data type

string

Alias
SNOMED CT 2010_0731
423740007
Karnofsky performance status
Description

Karnofsky performance status

Data type

string

Alias
SNOMED CT 2010_0731
273546003
White blood cell count
Description

WBC

Data type

string

Alias
SNOMED CT 2010_0731
767002
LOINC
6690-2
Platelet count - finding
Description

Platelet count - finding (Code )

Data type

string

Alias
SNOMED CT 2010_0731
365632008
UMLS CUI
C1287267
LOINC
777-3
Bilirubin
Description

Bilirubin

Data type

string

Alias
SNOMED CT 2010_0731
79706000
UMLS CUI
C0011221
LOINC
1975-2
Hepatitis
Description

Hepatitis

Data type

string

Alias
SNOMED CT 2010_0731
29001004
UMLS CUI
C0019158
Creatinine
Description

Creatinine

Data type

string

Alias
UMLS CUI
C0010294
SNOMED CT 2010_0731
15373003
LOINC
38483-4
MedDRA 13.1
10011358
Canadian Cardiovascular Society classification of angina
Description

Canadian Cardiovascular Society classification of angina (Code )

Data type

string

Alias
UMLS CUI
C1277207
SNOMED CT 2010_0731
134438001
NYHA class
Description

New York Heart Association Classification

Data type

string

Alias
UMLS CUI
C1275491
SNOMED CT 2010_0731
420816009
Ejection fraction
Description

Cardiac ejection fraction

Data type

string

Alias
UMLS CUI
C0232174
SNOMED CT 2010_0731
70822001
FEV1/VC ratio
Description

Forced expired volume in one second/vital capacity ratio

Data type

string

Alias
UMLS CUI
C0429744
SNOMED CT 2010_0731
251943006
Diffusion capacity
Description

Diffusion capacity of lung

Data type

string

Alias
UMLS CUI
C0231971
SNOMED CT 2010_0731
54715006
Diabetes mellitus
Description

Diabetes mellitus

Data type

string

Alias
UMLS CUI
C0011849
SNOMED CT 2010_0731
191044006
Hypersensitivity to medication
Description

Allergic reaction, due to correct medicinal substance properly administered

Data type

string

Alias
UMLS CUI
C0274302
SNOMED CT 2010_0731
57302007
HIV negative
Description

HIV negative

Data type

string

Alias
UMLS CUI
C0481430
SNOMED CT 2010_0731
143223008
Chemotherapy
Description

Chemotherapy

Data type

string

Alias
UMLS CUI
C0392920
SNOMED CT 2010_0731
150415003
Radiotherapy
Description

Radiotherapy

Data type

string

Alias
UMLS CUI
C1522449
SNOMED CT 2010_0731
302505005
Enrollment
Description

Enrollment

Data type

string

Alias
UMLS CUI
C1516879
Therapeutic procedure
Description

Therapeutic procedure

Data type

string

Alias
UMLS CUI
C0087111

Similar models

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Disease characteristics
Aggressive non-Hodgkin's lymphoma (NHL)
Item
Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement); CD20^+ B-cell lymphoma or CD20^- B-cell and T-cell lymphoma allowed
boolean
B-cell NHL
Item
B-cell NHL including the following: Stage III follicular lymphoma; Stage III follicular lymphoma and diffuse B-cell lymphoma; Lymphoblastic precursor B-cell lymphoma; Diffuse large cell B-cell lymphoma; Centroblastic; Immunoblastic; Plasmablastic; Anaplastic large cell; T-cell-rich B-cell lymphoma; Primary effusion lymphoma; Intravasal B-cell lymphoma; Primary mediastinal B-cell lymphoma; Mantle zone lymphoma, blastoid; Burkitt's lymphoma; Burkitt-like lymphoma; Aggressive marginal zone lymphoma (monocytoid)
boolean
T-cell NHL
Item
T-cell NHL including the following: Lymphoblastic precursor T-cell lymphoma; Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS); Lennert's lymphoma; T-zone lymphoma; T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type; Anaplastic large cell lymphoma; ALK^+ - ALK^-; Extranodal NK/T-cell lymphoma, nasal type; Intestinal T/NK-cell lymphoma (with or without enteropathy); Hepatosplenic gamma-delta lymphoma; Subcutaneous panniculitis-like PTCL; Aggressive T/NK PTCL; Anaplastic large-cell NHL, NOS
boolean
Bone marrow
Item
Bone marrow involvement no more than 25%
boolean
CNS / GI
Item
No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract
boolean
Item Group
Patient characteristics and prior concurrent therapy
Age
Item
Age 61 to 80
boolean
Performance Status
Item
ECOG 0-2 OR - Karnofsky 60-100%
boolean
Hematopoietic
Item
WBC at least 2,500/mm^3; Platelet count at least 100,000/mm^3
boolean
Hepatic
Item
Bilirubin no greater than 2 times upper limit of normal (ULN); No active hepatitis infection
boolean
Renal
Item
Creatinine no greater than 2 times ULN
boolean
Cardiovascular
Item
No Canadian Cardiovascular Society class III or IV angina pectoris; No New York Heart Association class III or IV cardiac failure; Ejection fraction at least 50%; Fractional shortenings at least 25% by echocardiography or nuclear medicine examination
boolean
Pulmonary
Item
FEV1 at least 50%; Diffusion capacity at least 50%
boolean
Other
Item
No uncontrolled diabetes mellitus; No known hypersensitivity to any study medications; No other concurrent malignancy; HIV negative
boolean
Prior concurrent therapy
Item
No prior chemotherapy; No prior radiotherapy; Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study); No other concurrent lymphoma therapy; No concurrent participation in another treatment study
boolean
Item Group
Medical Concepts
Diagnosis
Item
Diagnosis
string
C0011900 (UMLS CUI)
439401001 (SNOMED CT 2010_0731)
Diagnostic Neoplasm Staging
Item
Diagnostic Neoplasm Staging
string
C0027646 (UMLS CUI)
Bone Marrow Involvement
Item
Bone Marrow Involvement
string
C1517677 (UMLS CUI)
Age
Item
Age
string
C0001779 (UMLS CUI)
102518004 (SNOMED CT 2010_0731)
ECOG performance status
Item
ECOG performance status
string
423740007 (SNOMED CT 2010_0731)
Karnofsky performance status
Item
Karnofsky performance status
string
273546003 (SNOMED CT 2010_0731)
WBC
Item
White blood cell count
string
767002 (SNOMED CT 2010_0731)
6690-2 (LOINC)
Platelet count - finding (Code )
Item
Platelet count - finding
string
365632008 (SNOMED CT 2010_0731)
C1287267 (UMLS CUI)
777-3 (LOINC)
Bilirubin
Item
Bilirubin
string
79706000 (SNOMED CT 2010_0731)
C0011221 (UMLS CUI)
1975-2 (LOINC)
Hepatitis
Item
Hepatitis
string
29001004 (SNOMED CT 2010_0731)
C0019158 (UMLS CUI)
Creatinine
Item
Creatinine
string
C0010294 (UMLS CUI)
15373003 (SNOMED CT 2010_0731)
38483-4 (LOINC)
10011358 (MedDRA 13.1)
Canadian Cardiovascular Society classification of angina (Code )
Item
Canadian Cardiovascular Society classification of angina
string
C1277207 (UMLS CUI)
134438001 (SNOMED CT 2010_0731)
New York Heart Association Classification
Item
NYHA class
string
C1275491 (UMLS CUI)
420816009 (SNOMED CT 2010_0731)
Cardiac ejection fraction
Item
Ejection fraction
string
C0232174 (UMLS CUI)
70822001 (SNOMED CT 2010_0731)
Forced expired volume in one second/vital capacity ratio
Item
FEV1/VC ratio
string
C0429744 (UMLS CUI)
251943006 (SNOMED CT 2010_0731)
Diffusion capacity of lung
Item
Diffusion capacity
string
C0231971 (UMLS CUI)
54715006 (SNOMED CT 2010_0731)
Diabetes mellitus
Item
Diabetes mellitus
string
C0011849 (UMLS CUI)
191044006 (SNOMED CT 2010_0731)
Allergic reaction, due to correct medicinal substance properly administered
Item
Hypersensitivity to medication
string
C0274302 (UMLS CUI)
57302007 (SNOMED CT 2010_0731)
HIV negative
Item
HIV negative
string
C0481430 (UMLS CUI)
143223008 (SNOMED CT 2010_0731)
Chemotherapy
Item
Chemotherapy
string
C0392920 (UMLS CUI)
150415003 (SNOMED CT 2010_0731)
Radiotherapy
Item
Radiotherapy
string
C1522449 (UMLS CUI)
302505005 (SNOMED CT 2010_0731)
Enrollment
Item
Enrollment
string
C1516879 (UMLS CUI)
Therapeutic procedure
Item
Therapeutic procedure
string
C0087111 (UMLS CUI)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial